Anti-CD20 (Obinutuzumab biosimilar - IgG1 isotype)

Product Unit size Cat. code Docs. Qty. Price


Human CD20 (Obinutuzumab) antibody - Human IgG1

Show product

100 µg

3 x 100 µg


Human IgG1 monoclonal antibody (mAb) against human CD20

Effector functions of mAb isotypes targeting CD20

Anti-hCD20-Ga-hIgG1 features the constant region (Fc) of a human IgG1 isotype and the variable region of obinutuzumab. Obinutuzumab, formerly named Afutuzumab or GA101, targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.

Obinutuzumab is a type II (second generation) non-fucosylated, fully humanized IgG1 monoclonal antibody (mAb) with improved therapeutic efficacy compared to previously developed type I (first generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL) [1-3].


InvivoGen’s Anti-hCD20-Ga-hIgG1 is generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section).
InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc regions.


 Read our review on Antibody Isotypes



1. Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
2. Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.


CD20 cell surface staining using Anti-hCD20-Ga-hIgG1
CD20 cell surface staining using Anti-hCD20-Ga-hIgG1

Binding of Anti-hCD20-Ga-hIgG1 mAb to hCD20. EL4-hCD20 cells were incubated for 30 minutes at 4°C with 500 ng of Anti-hCD20-Ga-hIgG1 or an isotype control. Subsequently, a secondary PE-labeled antibody was added and incubated at 4°C for 30 minutes. The binding affinity was assessed using flow cytometry.

Back to the top


Target: Human CD20

Clonality: Monoclonal antibody

Source: CHO cells

Clone: Obinutuzumab (Anti-hCD20-hIgG1fut, kappa)

IsotypeHuman IgG1, kappa

Control: Human IgG1 control

Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Tested application: Flow cytometry

Quality control:

  • Binding of Anti-hCD20-Ga-hIgG1 to human CD20 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top


Anti-hCD20-Ga-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • hcd20ga-mab1: 100 µg
  • hcd20ga-mab1-03: 3 x 100 µg

room temperature Anti-hCD20-Ga-hIgG1 is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty